Predictive biomarkers for treatment response — the missing link in psoriatic arthritis clinical development

Psoriatic arthritis (PsA) has more effective therapies than ever, yet drug selection still relies on trial and error. Across 1,155 interventional PsA trials (Trialtrove, March 2026), phase III–IV confirmatory studies account for half of all activity, but no validated biomarker predicts which patient will respond to which mechanism. Most patients cycle through two or more biological or targeted-synthetic disease-modifying antirheumatic drugs (DMARDs) before remission, and difficult-to-manage and treatment-refractory PsA have only recently been formally defined. Our central claim is that the main barrier to precision medicine in PsA is no longer drug availability but the absence of response-predictive biomarkers. Two roles must be distinguished. Prognostic markers such as C-reactive protein (CRP) and baseline joint erosions, which predict a higher risk of radiographic progression, are now routinely used to enrich phase 3 PsA trials; the APEX and POETYK PsA-1 programmes require both elevated high-sensitivity CRP and radiographically confirmed erosions. Because CRP elevation predicts better response across tumour necrosis factor, interleukin (IL)-17, IL-23 and tyrosine kinase 2 inhibition alike, however, it cannot discriminate between mechanisms: enrichment for risk is not selection by predicted benefit. Response prediction is feasible: COSMOS and DISCOVER substudies show baseline IL-22, IL-17A/F and IFNγ levels track later guselkumab response. We propose three steps: standardized biospecimen collection in phase 3 PsA trials, pre-specified mechanism-matched predictive panels, and—contingent on validated cross-tissue markers—biomarker-guided adaptive trials in difficult-to-treat PsA. Closing this gap is the decisive step toward treat-to-target precision medicine in PsA.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1988796
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Predictive biomarkers for treatment response — the missing link in psoriatic arthritis clinical development

Lifeng Ge, Huigen Lu
2 links
Frontiers in Immunology
Spondyloarthritis Studies and Treatments
article

Predictive biomarkers for treatment response — the missing link in psoriatic arthritis clinical development

Lifeng Ge, Huigen Lu
article en

Abstract

Psoriatic arthritis (PsA) has more effective therapies than ever, yet drug selection still relies on trial and error. Across 1,155 interventional PsA trials (Trialtrove, March 2026), phase III–IV confirmatory studies account for half of all activity, but no validated biomarker predicts which patient will respond to which mechanism. Most patients cycle through two or more biological or targeted-synthetic disease-modifying antirheumatic drugs (DMARDs) before remission, and difficult-to-manage and treatment-refractory PsA have only recently been formally defined. Our central claim is that the main barrier to precision medicine in PsA is no longer drug availability but the absence of response-predictive biomarkers. Two roles must be distinguished. Prognostic markers such as C-reactive protein (CRP) and baseline joint erosions, which predict a higher risk of radiographic progression, are now routinely used to enrich phase 3 PsA trials; the APEX and POETYK PsA-1 programmes require both elevated high-sensitivity CRP and radiographically confirmed erosions. Because CRP elevation predicts better response across tumour necrosis factor, interleukin (IL)-17, IL-23 and tyrosine kinase 2 inhibition alike, however, it cannot discriminate between mechanisms: enrichment for risk is not selection by predicted benefit. Response prediction is feasible: COSMOS and DISCOVER substudies show baseline IL-22, IL-17A/F and IFNγ levels track later guselkumab response. We propose three steps: standardized biospecimen collection in phase 3 PsA trials, pre-specified mechanism-matched predictive panels, and—contingent on validated cross-tissue markers—biomarker-guided adaptive trials in difficult-to-treat PsA. Closing this gap is the decisive step toward treat-to-target precision medicine in PsA.

Frontiers in ImmunologyVol. 17
Jiaxing University (CN)
Good health and well-being
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon